ArticleJournal of cellular and molecular medicine2020
TGFβ2 is a prognostic-related biomarker and correlated with immune infiltrates in gastric cancer.
Article in Journal of cellular and molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 49 citations in OpenAlex.
- Dual function of transforming growth factor beta 2 in the progression of gastric carcinoma.World journal of biological chemistry · 2026Article
- TGFβ2 Promotes the Construction of Fibrotic and Immunosuppressive Tumor Microenvironment in Pancreatic Adenocarcinoma: A Comprehensive Analysis.Molecular biotechnology · 2025Article
- Article
- MIRS: An AI scoring system for predicting the prognosis and therapy of breast cancer.iScience · 2023Article
- Identification of INHBA as a potential biomarker for gastric cancer through a comprehensive analysis.Scientific reports · 2023Article
- Glycolytic regulatory enzyme PFKFB3 as a prognostic and tumor microenvironment biomarker in human cancers.Aging · 2023Article
- The Silkworm Carboxypeptidase Inhibitor Prevents Gastric Cancer Cells' Proliferation through the EGF/EGFR Signaling Pathway.International journal of molecular sciences · 2023Article
- Comprehensive analysis of cuproptosis-related prognostic gene signature and tumor immune microenvironment in HCC.Frontiers in genetics · 2023Article
- Comprehensive Analysis Based on the Cancer Immunotherapy and Immune Activation of Gastric Cancer Patients.Genetics research · 2023Article
- Signaling pathways and therapeutic interventions in gastric cancer.Signal transduction and targeted therapy · 2022Review
- AFF3 is a novel prognostic biomarker and a potential target for immunotherapy in gastric cancer.Journal of clinical laboratory analysis · 2022Article
- Identification of Key Genes and Key Pathways in Breast Cancer Based on Machine Learning.Medical science monitor : international medical journal of experimental and clinical research · 2022Article
- Identification of AKIRIN2 as a potential biomarker and correlation with immunotherapy in gastric adenocarcinoma by integrated bioinformatics analysis.Scientific reports · 2022Article
- Article
- Long non-coding RNAs PGM5-AS1 upregulates Decorin (DCN) to inhibit cervical cancer progression by sponging miR-4284.Bioengineered · 2022Article
- Correlation of SIDT1 with Poor Prognosis and Immune Infiltration in Patients with Non-Small Cell Lung Cancer.International journal of general medicine · 2022Article
- PDGFRB is a potential prognostic biomarker and correlated with immune infiltrates in gastric cancer.Cancer biomarkers : section A of Disease markers · 2022Article
- Identification by Bioinformatics Analysis of Potential Key Genes Related to the Progression and Prognosis of Gastric Cancer.Frontiers in oncology · 2022Article
- Characterization of Immune-Related Molecular Subtypes and a Prognostic Signature Correlating With the Response to Immunotherapy in Patients With Gastric Cancer.Frontiers in immunology · 2022Article
- Association of the TGFβ gene family with microenvironmental features of gastric cancer and prediction of response to immunotherapy.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
TGFβ2 is an essential regulator of immune cell functionality, but the mechanisms whereby it drives immune infiltration in gastric cancer remain uncertain. The Oncomine and Tumor Immunoassay Resource (TIMER) databases were used for assessing the expression of TGFβ2, after which TIMER was used to explore the relationship between TGFβ2 and tumour immune infiltration. Finally, we assessed how TGFβ2 expression correlated with the expression of a set of marker genes associated with immune infiltration using TIMER and GEPIA. We determined TGFβ2 expression to be significantly correlated with outcome in multiple types of cancer in the Cancer Genome Atlas (TCGA), with the effect being particularly pronounced in gastric cancer. Furthermore, elevated TGFβ2 expression was found to be significantly correlated with gastric cancer N staging, and with the expression of a variety of immune markers associated with particular immune cell subsets. These results indicate that TGFΒ2 is associated with patient outcome and tumour immune cell infiltration in multiple cancer types. This suggests that TGFβ2 is a key factor which governs immune cell recruitment to gastric cancer tumours, potentially playing a vital role in governing immune cell infiltration and thus representing a valuable prognostic biomarker in gastric cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.